TABLE 1.
Characteristics of children (0‐17 years) and AYAs (18‐39 years) diagnosed with AML in the Netherlands between 1990 and 2015
| Characteristics | Total | Children (0‐17 years) | AYAs (18‐39 years) | ||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | P (χ 2) a | |
| Overall | 2058 | 675 | 1383 | ||||
| Median age at diagnosis in years, IQR | 26 | 21 | 6 | 12 | 31 | 11 | |
| Sex | .001 | ||||||
| Male | 1040 | 50.5 | 377 | 55.9 | 663 | 47.9 | |
| Female | 1018 | 49.5 | 298 | 44.2 | 720 | 52.1 | |
| Period of diagnosis | .04 | ||||||
| 1990‐1999 | 833 | 40.5 | 247 | 36.6 | 586 | 42.4 | |
| 2000‐2009 | 769 | 37.4 | 270 | 40.0 | 499 | 36.1 | |
| 2010‐2015 | 456 | 22.2 | 158 | 23.4 | 298 | 21.6 | |
| Subtype | <.001 | ||||||
| APL | 202 | 9.8 | 34 | 5.0 | 168 | 12.2 | |
| ML‐DS | 28 | 1.4 | 28 | 4.2 | 0 | 0.0 | |
| Myeloid sarcoma | 21 | 1.0 | 9 | 1.3 | 12 | 0.9 | |
| CBF leukemia: t(8;21) or inv(16)/t(16;16) b | 174 | 8.5 | 95 | 14.1 | 79 | 5.7 | |
| AML other | 1633 | 79.4 | 509 | 75.4 | 1124 | 81.3 | |
| Site of primary treatment | <.001 | ||||||
| Nonacademic hospital | 346 | 16.8 | 51 | 7.6 | 295 | 21.4 | |
| Academic hospital | 1711 | 83.2 | 624 | 92.4 | 1087 | 78.7 | |
| Therapy | |||||||
| Chemo | 1946 | 94.7 | 645 | 95.8 | 1301 | 94.1 | .11 |
| SCT | 744 | 36.2 | 155 | 23.0 | 589 | 42.6 | <.001 |
Notes: The % missing values was <1% for all variables included in this table. Statistically significant P values (P < .05) are displayed in bold.
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; AYAs, adolescents and young adults; CBF, core‐binding factor; IQR, interquartile range; ML‐DS, myeloid leukemia associated with Down syndrome; SCT, stem cell transplantation.
a
Fisher's Exact test was used instead of Pearson's Χ 2 test when N ≤ 5 in one or more categories.
b
CBF leukemia was more consistently tested and registered as from 2001.